Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genaera's development partner, MedImmune has started fourth Phase IIa clinical trial of MEDI-528, an anti-IL-9 monoclonal antibody targeting interleukin-9, in patients with asthma.
Subscribe to our email newsletter
MedImmune is currently evaluating MEDI-528 in patients with asthma in a series of Phase II clinical trials. The goal of the current Phase IIa trial is to assess the safety and tolerability of multiple fixed escalating doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction.
The study will also assess the effect of MEDI-528 on exercise challenge testing, as well as the pharmacokinetics and immunogenicity of the investigational treatment. Enrollment of this randomized, double-blind, placebo-controlled trial will take place at multiple sites throughout the US and Canada.
Jack Armstrong, president and CEO of Genaera, said: “The initiation of the exercise-induced bronchoconstriction trial represents another important step in the development of the anti-IL-9 antibody for mild to moderate asthma.”